MIRA Pharmaceuticals (MIRA) Up Over 400% on Positive Preclinical Study Results Related to Ketamine in Treatment of Neurological Disorders

Today the leading pre-clinical pharmaceutical company, MIRA Pharmaceuticals, Inc. (MIRA) announced new preclinical study results for its novel oral ketamine analog, Ketamir-2 which, is under investigation for its potential in treating neurological and neuropsychiatric disorders, including depression, treatment-resistant depression (TRD), and post-traumatic stress disorder (PTSD).

MIRA is in the process of submitting an Investigational New Drug (IND) to the FDA by the end of this year which would grant them the ability to test Ketamir-2 on humans.

The company previously announced that Ketamir-2’s oral bioavailability is predicted to be around 80%, significantly higher than traditional ketamine’s less than 30%. Preclinical studies have also demonstrated that oral Ketamir-2 is safe at high doses and effective in various anti-depressant and anxiolytic models. Moreover, it does not appear to cause hyper-locomotor activity, a common side effect associated with traditional ketamine.

Dr. Itzchak Angel, Chief Scientific Advisor of MIRA Pharmaceuticals, stated, “Our findings on Ketamir-2 underline its potential as a groundbreaking treatment for mental health disorders. We are committed to advancing Ketamir-2 towards clinical trials and making this innovative treatment available to patients in need.”

MIRA currently leads the PRISM Psychedelics Index and is up over 400% on the day upon the release of this news.